Jupiter Topco LLC Makes New Investment in Enovis Corporation $ENOV

Key Points

• Jupiter Topco LLC acquired 113,355 Enovis shares worth approximately $2.35 million, representing a 0.20% stake. Institutional investors collectively own 98.45% of the company.
• Analysts maintain a generally positive outlook, with 10 Buy ratings, one Hold and one Sell; Enovis has a consensus rating of “Moderate Buy” and an average price target of $40.38, despite several recent target reductions.
• Enovis reported quarterly EPS of $0.90, exceeding estimates of $0.85, while revenue rose 3.2% year over year to $582.78 million. The stock opened at $20.26, near its 52-week low of $19.14.

Jupiter Topco LLC acquired a new position in shares of Enovis Corporation (NYSE:ENOV - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 113,355 shares of the company's stock, valued at approximately $2,346,000. Jupiter Topco LLC owned 0.20% of Enovis as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company's stock valued at $1,622,000 after acquiring an additional 621 shares during the period. MGO One Seven LLC grew its holdings in Enovis by 9.4% in the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company's stock worth $202,000 after purchasing an additional 650 shares during the period. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC increased its stake in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock valued at $249,000 after purchasing an additional 749 shares in the last quarter. Finally, Arax Advisory Partners bought a new stake in Enovis in the fourth quarter valued at $29,000. Institutional investors own 98.45% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ENOV shares. Citizens Jmp cut their price objective on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a research report on Wednesday. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Evercore set a $32.00 price target on Enovis in a research note on Monday, July 6th. BTIG Research dropped their price target on Enovis from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Tuesday. Finally, Citigroup reiterated a "market outperform" rating on shares of Enovis in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enovis presently has an average rating of "Moderate Buy" and a consensus target price of $40.38.

Insider Transactions at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the business's stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company's stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders bought 3,200 shares of company stock worth $69,864. 2.90% of the stock is currently owned by insiders.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: The acquisition would expand Enovis’ ASTRA enabling-technology platform into orthopedic surgical robotics, adding robotic automation, imaging and navigation capabilities. Management expects the combination to improve surgical precision and workflow efficiency while creating a broader platform for future growth. Enovis acquisition announcement
• Positive Sentiment: Wells Fargo lowered its Enovis price target to $33 from $39 but maintained an “overweight” rating. Citizens JMP also reduced its target, to $47 from $55, while retaining a “market outperform” rating. The continued positive ratings indicate analysts see substantial long-term upside despite near-term concerns.
• Neutral Sentiment: Enovis plans to pay approximately €155 million, or about $180 million, for eCential Robotics. The transaction is intended to bring eCential’s surgical robot to market and broaden Enovis’ orthopedic technology portfolio. Enovis to acquire eCential Robotics for €155 million
• Negative Sentiment: Investors reacted negatively because the deal is expected to pressure Enovis’ margins in 2027. The acquisition also introduces execution, commercialization and integration risks as the company invests in developing and scaling the surgical robotics business. Shares have declined sharply following the announcement. Enovis drops after eCential acquisition offer

Enovis Stock Down 1.3%

Enovis stock opened at $20.26 on Thursday. Enovis Corporation has a 1-year low of $19.14 and a 1-year high of $34.28. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -1.05 and a beta of 1.31. The firm's fifty day moving average price is $25.63 and its two-hundred day moving average price is $24.26. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the previous year, the firm posted $0.79 earnings per share. The firm's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts predict that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source